Google (GOOGL.US)-backed AI pharmaceutical company Isomorphic Labs starts a new round of fundraising: received $2.1 billions just five months ago, this round aims for a $50 billions valuation.

智通财经2026/10/08 06:36

Show original

According to sources cited by Zhitong Finance APP, Isomorphic Labs, an AI drug development startup spun out from Google DeepMind, a subsidiary of Alphabet (GOOGL.US), is in preliminary talks for a new round of financing with a target valuation of at least $40 billion.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

TSMC’s October revenue reached 586.89 billion New Taiwan dollars, up 59.7% year-on-year

智通财经•2026/11/10 06:01

TSMC’s October sales reached 586.89 billion New Taiwan dollars, up 59.7% year-on-year

智通财经•2026/11/10 05:50

Precious metal price fluctuations, China Gold Coin Group issues risk warning

智通财经•2026/11/10 05:36

Jefferies lowers Tesla's target price to $375

智通财经•2026/11/10 05:30